(R)-(+)-Trityl glycidyl ether
Based on 1 Customer Validation
(R)-(+)-Trityl glycidyl ether, a heterocyclic compound, is a precursor that can be used to synthesize glycerophospholipids, as well as compounds with antiviral and antimalarial activities.
For research use only. We do not sell to patients.
- Purity : 97.0%
- CAS No.: 65291-30-7
- Formula: C22H20O2
- Molecular Weight:316.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B1337S1
Choline-d9 chlorideStable Isotope -
HY-N1581
QuassinAnti-plasmodial Agent -
HY-Z1630
Rivaroxaban impurity 6Drug Impurity -
HY-128026
MMP-9/MMP-13 Inhibitor IMMP-9/MMP-13 Inhibitor -
HY-N0402S
Artemether-d3Stable Isotope -
HY-W011434
Triglycidyl isocyanurateApoptosis Inducer -
HY-W099547
Dihexadecyl hydrogen phosphateBiochemical Assay Reagent -
HY-Y1361
Diethyl D-(-)-tartrateBiochemical Reagent -
HY-Z1630R
Rivaroxaban impurity 6 (Standard) -
HY-B1322AS
Amodiaquine-d10Stable Isotope -
HY-158721
PenicinolineSecondary Metabolite
Biological Activity
Description
Chemical Information
-
CAS No. 65291-30-7
-
Appearance Solid
-
Molecular Weight 316.39
-
Formula C22H20O2
-
Color White to off-white
-
SMILES
[C@@H]1(CO1)COC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (158.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Baszczyňski O, et al. Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines. Bioorg Med Chem. 2011 Apr 1;19(7):2114-24. [Content Brief]
[2]. Sato E, et al. Design, synthesis and anti-malarial activities of synthetic analogs of biselyngbyolide B, a Ca2+ pump inhibitor from marine cyanobacteria. Bioorg Med Chem Lett. 2018 Feb 1;28(3):298-301. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1607 mL | 15.8033 mL | 31.6066 mL | 79.0164 mL |
| 5 mM | 0.6321 mL | 3.1607 mL | 6.3213 mL | 15.8033 mL | |
| 10 mM | 0.3161 mL | 1.5803 mL | 3.1607 mL | 7.9016 mL | |
| 15 mM | 0.2107 mL | 1.0536 mL | 2.1071 mL | 5.2678 mL | |
| 20 mM | 0.1580 mL | 0.7902 mL | 1.5803 mL | 3.9508 mL | |
| 25 mM | 0.1264 mL | 0.6321 mL | 1.2643 mL | 3.1607 mL | |
| 30 mM | 0.1054 mL | 0.5268 mL | 1.0536 mL | 2.6339 mL | |
| 40 mM | 0.0790 mL | 0.3951 mL | 0.7902 mL | 1.9754 mL | |
| 50 mM | 0.0632 mL | 0.3161 mL | 0.6321 mL | 1.5803 mL | |
| 60 mM | 0.0527 mL | 0.2634 mL | 0.5268 mL | 1.3169 mL | |
| 80 mM | 0.0395 mL | 0.1975 mL | 0.3951 mL | 0.9877 mL | |
| 100 mM | 0.0316 mL | 0.1580 mL | 0.3161 mL | 0.7902 mL |
(R)-(+)-Trityl glycidyl ether Related Classifications
HY-W009194 Related Classifications
Powered by Bioz